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By Lorenzo Trippa and Giovanni Parmigiani
Dana-Farber Cancer Institute and Harvard School of Public Health
The purpose of cancer genome sequencing studies is to deter-
mine the nature and types of alterations present in a typical cancer
and to discover genes mutated at high frequencies. In this article we
discuss statistical methods for the analysis of somatic mutation fre-
quency data generated in these studies. We place special emphasis
on a two-stage study design introduced by Sjo¨blom et al. [Science
314 (2006) 268–274]. In this context, we describe and compare statis-
tical methods for constructing scores that can be used to prioritize
candidate genes for further investigation and to assess the statis-
tical significance of the candidates thus identified. Controversy has
surrounded the reliability of the false discovery rates estimates pro-
vided by the approximations used in early cancer genome studies.
To address these, we develop a semiparametric Bayesian model that
provides an accurate fit to the data. We use this model to generate
a large collection of realistic scenarios, and evaluate alternative ap-
proaches on this collection. Our assessment is impartial in that the
model used for generating data is not used by any of the approaches
compared. And is objective, in that the scenarios are generated by
a model that fits data. Our results quantify the conservative control
of the false discovery rate with the Benjamini and Hockberg method
compared to the empirical Bayes approach and the multiple testing
method proposed in Storey [J. R. Stat. Soc. Ser. B Stat. Methodol.
64 (2002) 479–498]. Simulation results also show a negligible depar-
ture from the target false discovery rate for the methodology used in
Sjo¨blom et al. [Science 314 (2006) 268–274].
1. Introduction. The systematic investigation of the genomes of human
cancers has recently become possible with improvements in sequencing and
bioinformatic technologies. Sjo¨blom et al. (2006) and Wood et al. (2007) de-
termined the sequence of comprehensive collections of coding genes (CCDS
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and RefSeq) in colorectal and breast cancers, and provided a catalogue of
somatic mutations. In this context, a somatic mutation is a tumor-specific
mutation not present in the germline of the patient whose tumor contained
it. Subsequently, Greenman et al. (2006) investigated somatic mutations in
the coding exons of 518 protein kinase genes in a large and diverse set of
human cancers. More recently, mutation data from glioblastoma tissues have
been studied in the The Cancer Genome Atlas project (2008) and Parsons
et al. (2008), and from pancreatic cancer in Jones et al. (2008). Statistical
analysis of the data generated in these studies poses new challenges that are
worthy of careful consideration. Greenman et al. (2006) have provided an
in-depth analysis of data generated by one-stage studies. To make optimal
use of sequencing resources, Sjo¨blom et al. (2006) introduced a two-stage de-
sign, with the stages termed “Discovery” and “Validation.” The Discovery
Stage consists of a catalog of mutations in all genes considered, for exam-
ple, all genes in the CCDS database. This design permitted selection of the
subset of genes that harbored at least one somatic mutation, termed “Dis-
covered.” This subset was further investigated in a Validation Stage which
cataloged somatic mutations in discovered genes in an independent set of
tumor samples. Genes that were mutated in at least one tumor in the Valida-
tion set were termed “Validated.” In this article we consider this two-stage
design. Sjo¨blom et al. (2006) and Wood et al. (2007), adopting this experi-
mental design, discovered that among the genes whose mutations are likely
responsible for carcinogenesis, the majority, the “hills,” had mutations in
small subgroups of cases, while only a handful of genes, the “mountains,”
were mutated in large subgroups. Thus, the hills and not the mountains
dominate the cancer genome landscape. This imbalance emphasizes the im-
portance of statistical methods in identifying the mutations involved in the
carcinogenesis process.
The somatic mutations found in cancer tissues are either “drivers” or
“passengers” [Wood et al. (2007)]. Driver mutations are causally involved
in the neoplastic process and are positively selected during tumorigenesis.
Passenger mutations provide no positive or negative selective advantage to
the tumor but are retained by chance during repeated rounds of cell division
and clonal expansion. The overarching goal of the statistical analysis of
cancer mutation data is to identify genes that are most likely to contain
driver mutations on the basis of their mutation type and frequency. This
is done by quantifying the evidence that the mutations in a gene reflect
underlying mutation rates that are higher than the passenger rates.
Early cancer genome projects provided a rank order of genes by their
potential to be drivers of carcinogenesis based on mutation frequencies in
tumors as well as the genes’ size and nucleotide compositions. To provide an
indication of the significance of lists of possible driver genes, they also pro-
vided estimates of the false discovery rate (FDR), that is, the expected pro-
portion of putative drivers that are actually passengers, or the proportion of
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erroneously rejected null hypotheses [Benjamini and Hochberg (1995)]. Since
the seminal article of Benjamini and Hochberg (1995), several authors have
proposed alternative methods that control the FDR with improved oper-
ating characteristics. Important contributions include relaxing the indepen-
dence assumption among the test statistics and handling discrete statistics
[Benjamini and Yekutieli (2001)]. Reviews are given in Dudoit, Shaffer and
Boldrick (2003), Cheng and Pounds (2007) and Farcomeni (2008). Despite
a rich literature, applications often include heuristic arguments and, in most
cases, the choice of a method is far from trivial: a trade-off arises between
methods which have been proved through rigorous analytical arguments to
control the FDR under a specified threshold and less conservative proce-
dures that rely on heuristic arguments, examples and asymptotic theory.
The trade-off between methodological rigor and operating characteristics
becomes particularly relevant, for example, when the independence hypoth-
esis is inappropriate or when data are highly discrete. Applications often
ignore these problems.
In this article we consider methods that are specific to somatic mutation
analysis, and assess them by a novel model-based approach. Our idea is to
develop a “super partes” model that can be used to provide highly realistic
artificial datasets for method evaluation. We refer to these as data-driven
simulated scenarios. Our scheme for evaluating alternative methods can take
into account possible discrepancies between methods’ assumptions and the
data. We apply this comparison method by revisiting the Sjo¨blom et al.
(2006) methodology as well as the alternative approaches proposed shortly
afterward by several groups [Forrest and Cavet (2007), Getz et al. (2007),
Rubin and Green (2007) and Parmigiani et al. (2007a, 2007b)]. We discuss
the application of this scheme to the data collected in Wood et al. (2007).
The article is structured in 5 sections. In Section 2 we introduce the
notation for modeling mutation counts in tumor tissues and present our
probability model. In Section 3 we briefly review techniques for controlling
or estimating false discovery rates, and specific approaches for the analysis
of somatic mutation data. In Section 4 we compare these approaches. Final
remarks are given in Section 5.
2. Data-driven simulation scenarios.
2.1. Approach. The idea of data-driven simulations is structured in two
steps. First we select a flexible probability model for the observed mutations.
The model includes model-specific parameters, genes-specific latent variables
and observable mutation counts. The model is consistent with widely estab-
lished assumptions on carcinogenesis. Prior distributions on the unknown
model parameters are specified by using both external experimental results
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and heuristic data-driven approaches. Second, we infer the genes-specific la-
tent variables, including driver status, through a Monte Carlo Markov chain
(MCMC) algorithm and generate simulated data sets consistent with the
Wood et al. (2007) study.
Throughout the article this Bayesian model is used only for generating
simulated data sets that are highly consistent with the observed data in
Wood et al. (2007) and are impartial to the FDR approaches examined. In
principle, the model could be used directly for selecting genes having high
posterior probabilities of being drivers. Other potential applications of the
model include (i) predicting the experimental outcomes for ongoing studies,
(ii) optimally choosing the resource allocation for the validation stage using
a decision theoretic approach and, more generally, (iii) developing adaptive
strategies for sequencing experiments. Nevertheless, here we prefer limiting
our comparisons to highly computationally efficient methods whose operat-
ing characteristics can be assessed via Monte Carlo techniques over a large
number of data sets. Moreover, it would be circular to simultaneously use
our Bayesian model for FDR estimation and for generating data for eval-
uation. As noted in Getz et al. (2007), the performance of some methods
could be sensitive to the distribution underlying the experimental data; us-
ing a probability model that fits the observed data, but also averages across
plausible values of the unknown parameters, allows us to provide appropri-
ately objective comparisons.
2.2. Sampling model. While cancer genome sequencing projects produce
a wealth of information, in this article we will focus on the somatic mutation
counts, broken down by gene and context, and considered separately for the
Discovery and Validation Stages. Table 1 summarizes the notation we will
use. Our model applies to a single disease, say, colorectal cancer, at a time.
Table 1
Summary of notation for the data produced by the study for the gth gene,
and associated gene-specific parameters
Mutation counts
X1gm number of mutations of type m detected in gene g in the Discovery Stage.
X2gm number of mutations of type m detected in gene g in the Validation Stage.
Coverage
T 1gm coverage of type m in gene g in the Discovery Stage.
T 2gm coverage of type m in gene g in the Validation Stage.
Mutation rates
γ1m rate of mutation of type m in the Discovery Stage.
γ2m rate of mutation of type m in the Validation Stage.
θg multiplicative gene-specific random effect.
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The probability model is defined on the basis of a few well-established as-
sumptions that allow to specify a distribution of mutation counts conditional
on unknown gene-specific mutation rates. Using latent variables, we spec-
ify a model allowing for unknown composition of the genome in terms of
passengers and drivers, and for heterogeneous mutation rates across driver
genes. More formally, we assume that, for each gene and sample, the number
of mutations of type m, that is, the number of identical mutations that can
occur only in a specific context, for example, C to G in a CpG locus, is
a mixture of Poisson distributions,
Xigm|θg, ρi, ηm ∼ Poisson(ρiηmθgTigm) and θg
i.i.d.
∼ F,(2.1)
where i indexes a tumor, g indexes a gene and Tigm denotes the coverage,
or the number of successfully sequenced nucleotides susceptible to mutation
of type m in gene g and sample i. The parameter ηm represents the rate
of mutations of type m among passengers. The multiplicative factor ρi is
designed to capture the fact that the abundance of mutations varies across
tumors. The transition of a tissue from normal to cancer can be described
as a progressive accumulation of mutations, some of them are drivers and
some are passengers. This dynamic varies across tumors; such heterogeneity
is the focus of a significant portion of cancer research; see Stratton, Campbell
and Futreal (2009) for a stimulating discussion. Our model, as well as those
used in the previously mentioned cancer studies, describes a snapshot of
this dynamic process at the time of sequencing. The product (ρiηm) can
be interpreted as the rate of mutations of type m in tumor i, assuming
that the nucleotide is part of a passenger gene. The gene-specific latent
variables θg capture gene-specific variation across the genome; if θg = 1,
gene g is a passenger, while higher values identify the drivers. Our model
assumes that the rates of mutation across different types m of mutations
in a single gene g are proportional to the rates of mutation in a passenger
gene. Finally, F is the distribution of θg’s across the genome. It allows for
values of 1 or bigger and allows for a concentration of mass on the value
of 1, corresponding to the passengers.
The overall structure of the model reflects the assumption that the drivers
have higher rates of mutation than the passengers. The analyses in Sjo¨blom
et al. (2006) and Wood et al. (2007) were aimed at selecting cancer genes
with mutation rates higher than the hypothesized passenger rates. The use
of the Poisson distribution in (2.1) is motivated by the fact that, under
mild assumptions, it well approximates a more rigorous multinomial model
[Wood et al. (2007)] obtained by modeling possible mutations in a single
gene as binary variables.
Values of individual passenger rates (ρiηm) can be obtained using data
external to the somatic mutations counts [Sjo¨blom et al. (2006), Wood et al.
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(2007)]. This allows us to simplify the model (2.1) by collapsing data across
patients. Once the intensities (ρiηm) are known, the collapsed counts data
(Xgm =
∑
iXigm) are sufficient statistics for evaluating the likelihood func-
tion. This allows for a considerable reduction of the computational require-
ments. We will thus use the alternative representation of (2.1):
Xgm|θg, γm ∼ Poisson(γmθgTgm) and θg
i.i.d.
∼ F,(2.2)
where Xgm is the total number of mutations of type m harbored in the gth
gene, Tgm =
∑
i Tigm and Tgmγm =
∑
i ρiηmTigm.
Multistage designs are attractive strategies for identifying cancer genes;
the first stage indicates a subset of genes that are more likely to be drivers
and, in the subsequent phase, only this subset is analyzed. Relevant cost–
effectiveness analysis and comparisons of alternative designs for genome-
wide studies are illustrated in Satagopan et al. (2002), Satagopan and Elston
(2003), Satagopan, Venkatraman and Begg (2004), Kraft (2006), Skol et al.
(2006), Wang and Stram (2006) and Parmigiani et al. (2009). In the studies
discussed by Sjo¨blom et al. (2006) and Wood et al. (2007), at the end of the
first stage all genes which harbored one or more mutations are considered
for further study. We will use the notation X1gm and X
2
gm for denoting the
number of mutations in the two phases. Similarly, T 1gm and T
2
gm denote the
coverages and (γ1m, γ
2
m) the rates for the discovery and validation phases.
Model (2.2) can be adapted to the two-stage design as follows:
X1gm|θg, γ
1
m ∼ Poisson(γ
1
mθgT
1
gm),
X2gm|X
1
gm, θg, γ
1
m ∼
{
0, if X1gm = 0,
Poisson(γ2mθgT
2
gm), if X
1
gm > 0,
(2.3)
θg
i.i.d.
∼ F.
In these expressions the coverages T 1gm and T
2
gm are considered fixed. While
some variation may be experimentally observed, this is unlikely to be re-
lated to a gene’s driver status, and, thus, it is appropriate to model the
data conditionally on the coverages. For our purpose, the following three
considerations are critical:
Two-stage design. Only genes that harbor at least one mutation in the
Discovery Stage are sequenced in the Validation Stage. This screening condi-
tion needs to be taken into account when assessing significance using p-values
or other methods that rely on the sampling distribution.
Coverage. The number of nucleotides successfully sequenced is generally
smaller than the gene length times the number of tumors analyzed. For
example, certain exons may be technically challenging to sequence. It is
appropriate to apply stringent quality criteria to sequencing data, which
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lead to the exclusion of nucleotides whose sequence could not be identified
with certainty. Nucleotides excluded, or not covered, should not be included
in statistical evaluations. In what follows p-values and other statistics used
for prioritizing putative driver genes are computed taking into account, for
each gene, which loci have been sequenced.
Context. The third consideration involves the observed bases in the muta-
tions. In sequencing studies, the precise bases that comprise the mutation, as
well as the neighboring bases, termed “mutation contexts,” are important.
We use a classification of contexts provided in Wood et al. (2007). This is
a partition of the sequenced basis. For our purpose, it is relevant that each
subset has specific rates of mutation under the passenger status. This fact
implies that the priority given to a gene in further studies and the statistical
significance of a gene should depend not only on the number of nucleotides
but also on the gene-specific basis sequence.
2.3. A Bayesian approach to generating simulation scenarios. For our
analysis we propose embedding the sampling model (2.3) in a Bayesian semi-
parametric model. This will allow us to generate possible scenarios consistent
with the data from the Wood et al. (2007) study. We use a Dirichlet process
prior [Ferguson (1973)] for the unknown distribution F ,
F ∼Dirichlet(A),(2.4)
where A is a positive measure on [1,∞). Reviews on the Dirichlet process
and applications in biostatistics are given in Dunson (2010) and Mu¨ller and
Quintana (2004).
We chose the Dirichlet mixture model because of its flexibility compared
to alternative parametric prior distributions. Simple preliminary analysis of
the mutation data shows that the so-called mountains can have mutation
rates over 100-folds higher than the passengers, while hills have markedly
lower rates. To capture both the mountains and the hills, we specify a suf-
ficiently flexible prior on the unknown mixing distribution F . As shown in
Venturini, Dominici and Parmigiani (2008), Bayesian mixtures model effec-
tively heavy tail distributions; in contrast, the posterior behavior of more
parsimonious parametric models can be strongly biased.
In order to generate scenarios consistent with the data in Wood et al.
(2007), we use a Monte Carlo Markov chain algorithm discussed in Escobar
and West (1995). The sampler is based on the Polya urn representation of
the Dirichlet process [Blackwell and MacQueen (1973)] and has been studied
for posterior simulation under the generic Dirichlet mixture model
p(X1, . . . ,Xn|F ) =
n∏
i=1
∫
p(Xi|θ)dF (θ), F ∼Dirichlet(A).
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The only condition for implementing the sampling scheme of Escobar and
West (1995) is that for every subset {i1, . . . , im} of distinct integers ranging
from 1 to n, the integral ∫ m∏
j=1
p(Xij |θ)dA(θ)(2.5)
can be easily computed. To this end, we specify the prior parameter A
proportional to a spiked distribution, including a point mass at {1} and
a shifted gamma distribution with support [1,∞), that is,
A(dx)∝ δ1(dx) + cI(x≥ 1)e
−a(x−1)(x− 1)b−1 dx,(2.6)
where δ1(·) is a Dirac measure, I(·) is the indicator function and a, b, c
are strictly positive. It can be verified that this choice of A allows us to
analytically solve integral (2.5).
We chose the mean of the random distribution F by a simple proce-
dure. We recall that the centering distribution of the Dirichlet process is
A(dx)/A([1,∞)); for every subset B of the real line, if 0<A(B)<A([1,∞)),
then F (B), a priori, is beta distributed, with mean A(B)/A([1,∞)); see Fer-
guson (1973). In order to specify the centering distribution, we first compute
the maximum likelihood estimator Fˆ of the mixing distribution in (2.3).
Then, we specify the parameter A({1})/A([1,∞)), this is the a priori ex-
pectation of the unknown proportion of passenger genes. In what follows
A({1})/A([1,∞)) is set equal to Fˆ ([1,2)). Finally, the parameterization of
the centering distribution is completed by setting a and b in (2.6) so that the
means and variances of the two distributions Fˆ (dx) and A(dx)/A([1,∞))
are identical. The steps outlined have clear interpretations, nevertheless, the
choice A({1})/A([1,∞)) = Fˆ ([1,2)) is, to some extent, arbitrary; we also im-
plemented posterior inference for alternative prior parameterizations: these
include A({1})/A([1,∞)) equal to Fˆ ([1,1.5)), Fˆ ([1,3)) and Fˆ ([1,4)). We
did not observe marked sensitivity; for example, the ratio between the max-
imum and the minimum posterior estimates of the number of drivers is equal
to 1.06.
We use the contexts and mutations classification discussed in Wood et al.
(2007). This classification is important because it allows us to account for
variations in the rates of mutations for passengers across loci, with rates
depending on the basis sequences. This classification includes 25 possible
types of mutations (m= 1, . . . ,25). The rates for the 1st and the 2nd stage
(γ1m and γ
2
m) were measured using SNP data. The SNP-based approach es-
timates the passenger mutation rates by comparing the nonsynonymous to
synonymous mutation ratios in cancer and normal tissues. This approach
has been considered in Wood et al. (2007). It estimates the passenger rates
using sequencing data from loci which are known for not contributing to
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carcinogenesis, and thus are not positively selected during carcinogenesis;
this characteristic is the defining feature of passenger genes.
A key advantage of the Bayesian estimate of the mixing distribution,
compared to the maximum likelihood estimate Fˆ , is that it allows us to
fully take into account the uncertainty on the distribution of rates across
genome, and to produce data sets under many different plausible versions
of this distribution.
The MCMC algorithm outlined, after a sufficient number of burn-in iter-
ations, produces approximate samples from the conditional distribution of
the latent variables given the data. The number of burn-in iterations can
be assessed by means of standard diagnostic procedures for MCMC meth-
ods; see, for example, Smith (2007). Each iteration of the MCMC algorithm
provides a collection of θg’s which is used as a simulation scenario. For each
scenario we generate a single data set X using (2.3). Each scenario can be
used to evaluate a given list of putative drivers by checking the proportion
of genes in the list for which θg = 1.
To highlight the excellent fit we obtain, Figure 1 provides an overview of
10,000 scenarios sampled by means of the proposed approach. Each itera-
tion attempts to reproduce the experiment on colorectal tumors discussed
in Wood et al. (2007). They considered 18,190 genes. During the discovery
phase, all genes were sequenced in 11 tumors. During the validation phase,
Fig. 1. Correspondence between simulated and observed counts of mutated genes in
10,000 simulated scenarios.
10 L. TRIPPA AND G. PARMIGIANI
769 genes were sequenced in 24 tumors. In the discovery phase, 17,421 genes
did not harbor any mutation, 716 genes harbored 1 mutation and 53 genes
harbored more than 1 mutation. In the validation phase, 609 did not harbor
any mutation, 115 harbored 1 and 45 harbored more than 1. Figure 1 repre-
sents the distribution, across the simulated scenarios, of the number of genes
harboring 0, 1 or more than 1 mutations in the two stages. As appropriate,
scenarios vary in their number of mutated genes found, while distributions
are centered around the observed data.
The data-driven simulation approach requires the variability across simu-
lations to be consistent with the data. In principle, if the experiment was re-
peated several times, one would like to observe a similar degree of variability
across simulations and across experiments. In practice, the degree of vari-
ability across simulations can be critically evaluated by means of inferential
arguments. The bootstrap method is specifically designed for predicting, on
the basis of a single experiment, the degree of variability across independent
replicates of the experiment. We compared the degree of variability across
simulations, illustrated in Figure 1, with the variability estimates obtained
by bootstrapping. Our application of the bootstrap builds on parametric es-
timates, for each gene, of the probabilities p(
∑
mX
1
gm = 1), p(
∑
mX
1
gm > 1),
p(
∑
mX
1
gm ≥ 1,
∑
mX
2
gm = 1) and p(
∑
mX
1
gm ≥ 1,
∑
mX
2
gm > 1), obtained
by fitting logistic binary regression models; these estimates are functions
of the gene-specific coverages T 1gm. The degree of uncertainty represented
in Figure 1 agrees with the bootstrap estimates; the ratios between the
standard deviations of the six univariate empirical distributions illustrated
in Figure 1 and the corresponding bootstrap estimates range between 1.03
and 1.17. Note that the six variables considered in Figure 1 define a coarse
partition of the genes; more generally, one can use the bootstrap method for
assessing the degree of variability of other marginal distributions.
3. Alternative methods for controlling the FDR. In this section we re-
view alternative FDR methods, we will then compare their operating char-
acteristics by means of the simulations described in the previous section.
3.1. The Benjamini and Hochberg, and the Storey procedures. Benjamini
and Hochberg (1995) considered which of the null hypotheses (Hg, g = 1, . . . ,
G), if any, should be rejected given p-values (Zg, g = 1, . . . ,G), one for each
hypothesis. They proposed a procedure for rejecting a (possibly empty) sub-
set of hypotheses so as to control the FDR, that is,
E
(
number of erroneously rejected hypotheses
number of rejected hypotheses
)
,(3.1)
with the proviso that the above ratio is 0 when none of the hypotheses is
rejected. The expectation in (3.1) is with respect to the unknown joint dis-
tribution of the test statistics Zg. The input of the procedure is the vector
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(Zg, g = 1, . . . ,G) and the output is the subset of rejected hypotheses. The p-
values corresponding to the true null hypothesis are independently uniformly
distributed. The FDR is an attractive error measurement in many applica-
tions with massive multiple hypotheses testing; we refer to Dudoit, Shaffer
and Boldrick (2003) for a comparison with alternative error measurements.
Let (Z(1), . . . ,Z(G)) be the sorted values in ascending order of the p-values
(Z1, . . . ,ZG) and let α ∈ (0,1) be any desired upper bound for the FDR.
Benjamini and Hochberg (1995) proved that the procedure that rejects the
hypotheses with a p-value lower than
max
{
{0} ∪
{
Z(g) :Z(g) <α
g
G
}}
(3.2)
controls the FDR below α. They show that, for every hypothetical propor-
tion p0 of the true null hypothesis,
FDR≤ p0α.(3.3)
The above inequality shows that the procedure is conservative. Storey (2002)
studied an alternative step-up method which starts from an estimate pˆ0 of
the proportion of the true null hypothesis and then set a threshold sim-
ilar to (3.2) indicating the rejection region. The estimate pˆ0 and the in-
equality (3.3) are used for inflating the upper bounds α(g/G), g = 1, . . . ,G,
in (3.2). The estimate of p0 is based on the right tail of the empirical distri-
bution of the p-values.
3.2. The empirical Bayes method. The use of empirical Bayes procedures
for estimating the FDR has been discussed by several authors, including
Efron et al. (2001), Efron (2003) and Dudoit, Gilbert and Laan (2008). In
this approach, one computes a data summary, or score Zg, that captures
departure from the null hypothesis, such as a p-value, a likelihood ratio
or other statistics. In our case, Zg should capture evidence for the rate of
mutation for gene g being higher than the passenger rate. The empirical
Bayes method is based on a mixture representation of the distribution of
these scores:
f(z) = p0f0(z) + (1− p0)f1(z);(3.4)
f(·) is the distribution of a randomly selected score, p0 is the unknown
proportion of true passengers, f0(·) is the distribution of a score randomly
selected among passengers and, finally, f1(·) is the distribution of scores
among drivers. The objectives are estimating the conditional probabilities
(1− p0)f1(Zg)
p0f0(Zg) + (1− p0)f1(Zg)
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and identifying a rejection region R containing the more significant scores,
such that ∫
R
p0f0(z)dz∫
R
p0f0(z) + (1− p0)f1(z)dz
≤ α;(3.5)
where α is the target ratio between the mistakenly rejected hypothesis and
the total number of rejections.
The distribution f0 can be approximated simulating the scores assuming
the genome only consists of passenger genes [Wood et al. (2007)], while the
distribution f and the proportion p0 are usually estimated by smoothing the
scores’ empirical distribution. Finally, expression (3.5) is used for rejecting
a subset of null hypothesis in such a way that the estimated proportion of
erroneously rejected null hypothesis is lower than α.
There is an important difference between the Benjamini and Hochberg
(1995) method and the empirical Bayes method. The former rejects a sub-
set of a list of null hypotheses and controls the expected proportion of er-
roneously rejected hypotheses. The latter, for a generic rejection region,
estimates the proportion of true null hypotheses; the investigator can then
select a subset of hypothesis such that the estimate is lower than a desired
threshold α.
3.3. The CaMP score. Sjo¨blom et al. (2006) introduced the cancer mu-
tation prevalence (CaMP) score, to provide a ranking of the Validated genes
and select promising candidates. The score is based on the probability of ob-
serving the number of actually found mutations if the gene was a passenger
gene, using a binomial model:
pg =


∏
m
(
T 1gm
X1gm
)
(γ1m)
X1gm(1− γ1m)
T 1gm−X
1
gm ,
∑
m
X1gm +X
2
gm = 0,
2∏
j=1
∏
m
(
T jgm
Xjgm
)
(γjm)
X
j
gm(1− γjm)
T
j
gm−X
j
gm ,
∑
m
X1gm > 0,
0, otherwise.
(3.6)
Recall that γ1m and γ
2
m are expected proportions of nucleotides, in a passen-
ger gene, harboring mutations of type m. The model takes into account the
two-stage experimental design.
We then rank the pg’s and call qg the resulting ranks. The CaMP score is
defined as
CaMPg(X
1
g1, . . . ,X
1
gM ,X
2
g1, . . . ,X
2
gM ) =−∞ if
∑
m
X2gm = 0
and
CaMPg(X
1
g1, . . . ,X
1
gM ,X
2
g1, . . . ,X
2
gM ) =− log10(pg/qg) if
∑
m
X2gm > 0.
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The top row corresponds to genes that are eliminated at the Discovery or
Validation Stage. The goal of the CaMP score is to rank genes according
to the strength of the evidence that they may be mutated at rates higher
than the passenger rates. An advantage of CaMP scores is that they can
be easily computed. This definition can also be seen as an approximation
of the Benjamini and Hochberg (1995) procedure. In Sjo¨blom et al. (2006)
a threshold of 1 on the CaMP scores was considered to generate a list of
putative drivers, with the goal of producing a list having approximately
10% of erroneously discovered drivers. The probabilities pg are not p-values
because they are not tail probabilities, but can be used as approximation of
the p-values if the expected number of mutations in each gene is close to 0.
Forrest and Cavet (2007) proposed to use tail probabilities for controlling
the FDR, though they use a sampling model that does not account for the
two-stage design. Getz et al. (2007) emphasized that p-values can be used
for controlling the FDR and proposed alternative test statistics. The closer
test statistics to the CaMP score are obtained by computing the distribu-
tion of pg, under the hypothesis that the gth gene is a passenger gene, and
evaluating the resulting tail probability. This procedure produces p-values
which can be used for controlling the FDR by applying the Benjamini and
Hochberg (1995) method. Getz et al. (2007) noted that the CaMP score is
not a monotone transformation of the probabilities pg; that is, given two
genes g′ and g′′, it can happen that pg′ < pg′′ and CaMPg′′ <CaMPg′ . Getz
et al. (2007) also discussed the idea of controlling the FDR by using the
log-likelihood ratio, that is,
log(p(Xg|θg))− log(p(Xg|θˆg)),
where θg represents the hypothesis that gene g is a passenger and θˆg is
the gene-specific maximum likelihood estimate. Rubin and Green (2007)
proposed to use the tail probabilities p(
∑
m=1Xgm ≥ x), based on the ag-
gregate number of mutations in a gene. These critiques of the analysis in
Sjo¨blom et al. (2006) and the alternatives proposed by these authors suggest
the idea of systematically assessing the operative characteristics of alterna-
tive approaches. Our comparisons in Section 4 consider the CaMP score and
the alternative p-values proposed by Getz et al. (2007), Forrest and Cavet
(2007) and Rubin and Green (2007). These alternative statistics are used for
implementing both the Benjamini and Hochberg (1995) method, the method
discussed in Storey (2002) and the Empirical Bayes method.
4. Simulation study. In this section we compare alternative methods for
identifying driver genes using the 10,000 simulation scenarios described in
Section 2. The Wood et al. (2007) study considered both colon and breast
tumors. Here we consider each tumor type separately, and repeat the same
analysis.
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Our simulation study compares the performance of alternative methods
for ranking cancer genes and selecting putative cancer genes. Table 2 pro-
vides the average operating characteristics across all the simulated scenarios.
All methods are set to control the FDR at 10% and 20% levels in turn. The
empirical Bayes method estimates the FDR: the investigator controls the
FDR by approximately matching the desired level α and the estimated pro-
portion of false discoveries. Table 2 shows the average proportion of genes
erroneously classified as drivers. Our results emphasize that operating char-
acteristics are quite conservative when the FDR is controlled, on the basis of
alternative p-values, using the Benjamini and Hochberg (1995) procedure.
They also illustrate the importance of quantifying this conservative behav-
ior by contrasting it with alternative methods such as the method proposed
in Storey (2002) and the Empirical Bayes method. The Bayesian model of
Section 2 allows us to simulate mutations across the genome, while the op-
erating characteristics of the alternative methods shown in Table 2 provide
Table 2
Operating Characteristics of 9 alternative procedures. Comparison between the Benjamini
and Hochberg (BH), Storey (ST) and empirical Bayes (EB) methods. The average
operating characteristics have been computed setting the FDR control at the 10% and
20% levels
False discoveries Average number of
proportion selected genes
Scores
Method or p-values α= 10% α= 20% α= 10% α= 20%
Colon-based simulations
BH CaMP score 0.101 0.218 150.4 221.8
BH p(
∑
Xjmg > x) 0.074 0.146 115.1 198.7
BH likelihood ratio 0.071 0.144 135.2 208.2
EB CaMP score 0.106 0.232 162.3 242.6
EB p(
∑
Xjmg > x) 0.100 0.238 147.8 250.4
EB likelihood ratio 0.102 0.211 163.8 237.2
ST CaMP score 0.104 0.220 157.3 235.4
ST p(
∑
Xjmg > x) 0.099 0.232 146.5 242.4
ST likelihood ratio 0.100 0.207 159.0 231.6
Breast-based simulations
BH CaMP score 0.098 0.196 146.6 218.8
BH p(
∑
Xjmg > x) 0.075 0.150 119.4 193.7
BH likelihood ratio 0.074 0.141 131.7 205.3
EB CaMP score 0.108 0.216 158.2 226.7
EB p(
∑
Xjmg > x) 0.105 0.225 139.6 235.0
EB likelihood ratio 0.098 0.209 153.5 223.4
ST CaMP score 0.103 0.213 157.6 219.5
ST p(
∑
Xjmg > x) 0.101 0.222 136.8 228.6
ST likelihood ratio 0.096 0.207 147.6 221.2
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approximations of their performances. The interpretation of the simulation
study is anchored to the modeling assumptions formalized in Section 2. The
results provide a solid basis for choosing among alternative methods.
All the methods considered produce lists of putative drivers genes with
an average misclassification error below the 11% when the control of the
FDR is set at the 10% level. If the desired α level is 10 %, our results in-
dicate that, when the CaMP scores are adopted, with the Benjamini and
Hochberg (1995) procedure, the average proportion of false discoveries is
approximately equal to α, while under the empirical Bayes method and
the Storey (2002) method, a slight excess of false discoveries is observed.
We note, both in the colon and breast simulation studies, that the use of
the likelihood ratios or the p-values p(
∑
Xjmg > x) with the Benjamini and
Hochberg (1995) procedure, on average, selects a substantially lower number
of putative drivers than the alternative approaches. When the likelihood ra-
tio and the p-value p(
∑
Xjmg >x) are compared, under the empirical Bayes
method and the Storey (2002) method, the likelihood ratio seams prefer-
able; the average proportions of false discoveries are similar, but the likeli-
hood ratio statistics select larger sets of putative drivers than the p-values
p(
∑
Xjmg > x). Also, when comparing the empirical Bayes method and the
Storey (2002) method based on the likelihood ratio statistics, we observed
only small variations both in the average proportion of false discoveries and
in the average number of putative drivers. The operating characteristics
when α is set at the 20% level confirm the conservative behavior of the
Benjamini and Hochberg (1995) procedure with the likelihood ratios or the
p-values p(
∑
Xjmg > x), but also show departures from the target FDR α of
the Empirical Bayes method and the Storey (2002) method. These results
hold for both colorectal and breast cancer. When α is equal to 20%, the
likelihood ratio seems preferable to the p-value p(
∑
Xjmg > x), under both
the empirical Bayes method and the Storey (2002) method; the likelihood
ratios select putatitive drivers with an average misclassification error closer
to the 20% target than the p-values.
The simulation-based comparison also allows us to asses the variability
of the false discoveries proportion across scenarios, summarized in Figure 2.
Each box plot is representative of the simulation-based distribution of the
proportion of erroneously rejected hypothesis. The degree of variability is
similar for all the methods considered; this similarity indicates that the
average operating characteristics concisely reported in Table 2 are sufficient
for a reliable evaluation of the methods.
To illustrate the importance of accounting for the two stages of the exper-
imental design in computing tail probabilities p(
∑
Xjmg > x), we repeated
the analysis ignoring the two-stage structure. That is, we computed the tail
probabilities under the erroneous assumption that the mutation counts were
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Fig. 2. The distribution of the true false discovery proportions across simulated sce-
narios. Each box plot corresponds to one of the methods (α = 10%) considered in the
simulation study. The lines of a box plot correspond to the median and to the 10th, 25th,
75th and 90th percentiles of the empirical distribution of the false discoveries proportion.
observed in a single stage experiment. We observed a substantial reduction
of the average number of selected genes, across simulation scenarios, when
the tail probabilities are used for implementing the Benjamini and Hochberg
(1995) procedure; with α= 20% in the colon cancer and breast cancer cases,
the averages become 165.6 and 157.0, respectively, and, with α= 10%, they
decrease to 98.4 and 96.2.
Another important question concerns the fidelity of the ranking provided
by these statistics. Figure 3 shows the Bayesian estimates of the left side of
the ROC curves corresponding to each of the scores considered. The ROC
curves are computed by separately estimating the scores’ distributions across
drivers and across passengers. The partial area under the curve is truncated
at the 2% specificity level. This is equal to 2.05× 10−3 for the log-likelihood
ratio test statistic, 1.94 × 10−3 for the p-values p(
∑
Xjmg > x) and 1.87 ×
10−3 for the CaMP scores. The ROC curves estimates suggest that the log-
likelihood ratio test statistic provides best discrimination, though differences
are small.
5. Discussion. The investigation of somatic alterations is of primary in-
terest in cancer research. Recent sequencing technologies have brought new
insight into this question by revealing a landscape characterized by muta-
tions involving a large number of driver genes, each altered in a relatively
small fraction of tumors. When the earlier of these studies began to emerge,
the cancer research community was faced with unexpected heterogeneity and
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Fig. 3. Estimated ROC curves for the log-likelihood ratio test statistics (solid line), the
p-values p(
∑
Xjmg >x) (dotted line) and the CaMP scores (dashed line).
complexity, which required a significant change of perspective in both basic
and clinical cancer investigations. The earliest genome-wide investigations
[Sjo¨blom et al. (2006)] proposed this change of landscape based on a rel-
ative small number of samples. A key element in support of this proposal
were estimates of the statistical significance of the reported list of driver
genes [Sjo¨blom et al. (2006)]. These estimates were challenged: alternative
approaches were proposed which would have led to reporting a drastically
reduced number of candidate drivers at the same significance level.
Subsequent studies have provided strong supporting evidence for this new
landscape, as well as validation for the driver role of many of the individual
genes initially identified in Sjo¨blom et al. (2006). However, from a statisti-
cal standpoint, it remains very interesting to understand whether the initial
conclusion was statistically sound based on the evidence available at the
time, in part because similar problems will arise again in other cancer types
and in other fields of genomics and evolutionary biology. Thus, our focus in
this article has been the rigorous evaluation of methods for the identifica-
tion of driver genes, with special emphasis on the methods that have been
instrumental in the change of landscape we just described.
In the statistical literature, two common approaches for the evaluation
of methodologies are asymptotic properties and scenario-based simulation
studies. Asymptotic conclusions can be difficult to extrapolate to small sam-
ples. Scenario-based simulations can lack objectivity and comprehensiveness,
and it can be a challenge to gauge whether the conclusions are applicable or
not to a specific context of interest. To overcome these difficulties, we have
proposed and implemented an alternative concept, which we hope will be
very broadly applicable across statistics, and contribute to a more objective
assessment of alternative methods. The idea is to construct a “super partes”
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model that is (a) independent of the approaches being compared; (b) fits the
data and available substantive knowledge well; and (c) can produce artificial
data sets accounting for all relevant uncertainties, including parameter and
potentially model uncertainty. This model is then used to simulate objective
data-driven scenarios for method comparison. In this article our implemen-
tation of the super-partes model is based on Bayesian nonparametrics, an
approach that can satisfy all three of the requirements above.
Strengths of the approach we proposed are the clear interpretation of both
the assumptions captured by the Bayesian model and the average operat-
ing characteristics. The probability model’s ability to reproduce the data
structure allows to effectively interpret the results. The proposed evaluation
scheme could be extended further to allow for more complex assumptions
such as dependency among genes belonging to common functional pathways.
When applied to the controversy surrounding FDR control of early cancer
genome studies, our method shows that the estimates provided in Sjo¨blom
et al. (2006) are quite accurate despite the approximations used. Also, the
Benjamini and Hochberg (1995) method is severely conservative. Last, the
Empirical Bayes method and the Storey method based on likelihood ra-
tios emerge as the preferred choices, though the margin of improvement is
dependent on the control level.
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